Table 3.
Endotype characteristics.
| Characteristic* | Endotype 1 | Endotype 2 | Endotype 3 | Endotype 4 |
|---|---|---|---|---|
| Patients, n (%) | 135 (26) | 100 (19) | 169 (32) | 124 (23) |
| Age, median years ‡ | 68.0 | 67.5 | 66.0 | 64.0 |
| Sex, % women | 46 | 42 | 42 | 27 |
| Death, %† | 1 | 6 | 21 | 43 |
| Hospice, %† | 4 | 5 | 3 | 6 |
| SNF, %† | 14 | 22 | 37 | 20 |
| Rehab, %† | 6 | 1 | 14 | 17 |
| Home, %† | 73 | 66 | 24 | 14 |
| LOS, median days† | 5 | 9 | 41 | 37 |
| Intubated, %† | 1 | 6 | 72 | 85 |
| Intubated, median days† | 14 | 7 | 34 | 31 |
| CKD, %† | 9 | 25 | 9 | 23 |
| ESRD, % | 3 | 10 | 1 | 4 |
| HTN, % | 55 | 70 | 61 | 70 |
| DM, %† | 27 | 53 | 37 | 42 |
| COPD, % | 10 | 7 | 4 | 2 |
| HFrEF | 10 | 11 | 1 | 6 |
| Obesity (BMI > 30), % | 27 | 22 | 25 | 35 |
| Azithromycin, %† | 18 | 24 | 51 | 57 |
| Enoxaparin, %† | 70 | 64 | 93 | 70 |
| Heparin, %† | 4 | 4 | 33 | 56 |
| Hydrocortisone, %† | 0 | 1 | 25 | 44 |
| Hydroxychloroquine, %† | 13 | 31 | 72 | 69 |
| Methylprednisolone, %† | 12 | 39 | 67 | 67 |
| Sarilumab, %† | 0 | 1 | 8 | 9 |
| Tocilizumab, %† | 1 | 5 | 24 | 30 |
| Famotidine, %† | 21 | 30 | 77 | 83 |
*
Characteristics are only shown if p < 0.05 indicating that values of the four groups are significantly different. Values are color-coded by characteristic from red (high) to black (median) to green (low). Number of patients included for reference, but no statistical test was run.
†
Denotes p < 0.001.
‡
Age included for reference in this table but was a feature used in clustering and p > 0.05.